Literature DB >> 34802148

Disposable point-of-care portable perfusion phantom for quantitative DCE-MRI.

Martin D Holland1, Andres Morales2, Sean Simmons3, Brandon Smith2, Samuel R Misko2, Xiaoyu Jiang4, David A Hormuth5, Chase Christenson5, Roy P Koomullil6, Desiree E Morgan7, Yufeng Li8, Junzhong Xu4, Thomas E Yankeelov5, Harrison Kim7.   

Abstract

PURPOSE: To develop a disposable point-of-care portable perfusion phantom (DP4) and validate its clinical utility in a multi-institutional setting for quantitative dynamic contrast-enhanced magnetic resonance imaging (qDCE-MRI).
METHODS: The DP4 phantom was designed for single-use and imaged concurrently with a human subject so that the phantom data can be utilized as the reference to detect errors in qDCE-MRI measurement of human tissues. The change of contrast-agent concentration in the phantom was measured using liquid chromatography-mass spectrometry. The repeatability of the contrast enhancement curve (CEC) was assessed with five phantoms in a single MRI scanner. Five healthy human subjects were recruited to evaluate the reproducibility of qDCE-MRI measurements. Each subject was imaged concurrently with the DP4 phantom at two institutes using three 3T MRI scanners from three different vendors. Pharmacokinetic (PK) parameters in the regions of liver, spleen, pancreas, and paravertebral muscle were calculated based on the Tofts model (TM), extended Tofts model (ETM), and shutter speed model (SSM). The reproducibility of each PK parameter over three measurements was evaluated with the intraclass correlation coefficient (ICC) and compared before and after DP4-based error correction.
RESULTS: The contrast-agent concentration in the DP4 phantom was linearly increased over 10 min (0.17 mM/min, measurement accuracy: 96%) after injecting gadoteridol (100 mM) at a constant rate (0.24 ml/s, 4 ml). The repeatability of the CEC within the phantom was 0.997 when assessed by the ICC. The reproducibility of the volume transfer constant, Ktrans , was the highest of the PK parameters regardless of the PK models. The ICCs of Ktrans in the TM, ETM, and SSM before DP4-based error correction were 0.34, 0.39, and 0.72, respectively, while those increased to 0.93, 0.98, and 0.86, respectively, after correction.
CONCLUSIONS: The DP4 phantom is reliable, portable, and capable of significantly improving the reproducibility of qDCE-MRI measurements.
© 2021 American Association of Physicists in Medicine.

Entities:  

Keywords:  DCE-MRI; abdomen; phantom; quantitative measurement

Mesh:

Substances:

Year:  2021        PMID: 34802148      PMCID: PMC9188826          DOI: 10.1002/mp.15372

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.506


  46 in total

1.  A feasible high spatiotemporal resolution breast DCE-MRI protocol for clinical settings.

Authors:  Luminita A Tudorica; Karen Y Oh; Nicole Roy; Mark D Kettler; Yiyi Chen; Stephanie L Hemmingson; Aneela Afzal; John W Grinstead; Gerhard Laub; Xin Li; Wei Huang
Journal:  Magn Reson Imaging       Date:  2012-07-06       Impact factor: 2.546

2.  Modification of population based arterial input function to incorporate individual variation.

Authors:  Harrison Kim
Journal:  Magn Reson Imaging       Date:  2017-09-27       Impact factor: 2.546

3.  Expiration-phase template-based motion correction of free-breathing abdominal dynamic contrast enhanced MRI.

Authors:  Zhang Li; Jeroen A W Tielbeek; Matthan W A Caan; Carl A J Puylaert; Manon L W Ziech; Chung Y Nio; Jaap Stoker; Lucas J van Vliet; Frans M Vos
Journal:  IEEE Trans Biomed Eng       Date:  2014-12-23       Impact factor: 4.538

4.  T₁ mapping using variable flip angle SPGR data with flip angle correction.

Authors:  Gilad Liberman; Yoram Louzoun; Dafna Ben Bashat
Journal:  J Magn Reson Imaging       Date:  2013-11-25       Impact factor: 4.813

5.  Semiautomatic determination of arterial input function in DCE-MRI of the abdomen.

Authors:  Harrison Kim; Desiree E Morgan
Journal:  J Biomed Eng Med Imaging       Date:  2017-04-28

6.  Dynamic NMR effects in breast cancer dynamic-contrast-enhanced MRI.

Authors:  Xin Li; Wei Huang; Elizabeth A Morris; Luminita A Tudorica; Venkatraman E Seshan; William D Rooney; Ian Tagge; Ya Wang; Jingang Xu; Charles S Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-13       Impact factor: 11.205

Review 7.  Quantifying blood-brain barrier leakage in small vessel disease: Review and consensus recommendations.

Authors:  Michael J Thrippleton; Walter H Backes; Steven Sourbron; Michael Ingrisch; Matthias J P van Osch; Martin Dichgans; Franz Fazekas; Stefan Ropele; Richard Frayne; Robert J van Oostenbrugge; Eric E Smith; Joanna M Wardlaw
Journal:  Alzheimers Dement       Date:  2019-04-25       Impact factor: 21.566

8.  Portable Perfusion Phantom Offers Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Accurate Prostate Cancer Grade Stratification: A Pilot Study.

Authors:  Harrison Kim; John V Thomas; Jeffrey W Nix; Jennifer B Gordetsky; Yufeng Li; Soroush Rais-Bahrami
Journal:  Acad Radiol       Date:  2020-03-27       Impact factor: 3.173

9.  Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation.

Authors:  Stephanie L Barnes; Jennifer G Whisenant; Mary E Loveless; Thomas E Yankeelov
Journal:  Pharmaceutics       Date:  2012       Impact factor: 6.321

10.  Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.

Authors:  Cathy C Zhang; Zhengming Yan; Anand Giddabasappa; Patrick B Lappin; Cory L Painter; Qin Zhang; Gang Li; James Goodman; Brett Simmons; Bernadette Pascual; Joseph Lee; Ted Levkoff; Tim Nichols; Zhiyong Xie
Journal:  Cancer Med       Date:  2014-02-27       Impact factor: 4.452

View more
  1 in total

Review 1.  Bone marrow MR perfusion imaging and potential for tumor evaluation.

Authors:  James F Griffith; R A van der Heijden
Journal:  Skeletal Radiol       Date:  2022-10-22       Impact factor: 2.128

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.